Hibiskus Biopharma
Kalamazoo
About Hibiskus Biopharma
Hibiskus Biopharma is an early-stage pharmaceutical venture pursuing the development of small-molecule cancer therapy, TIR-199. TIR-199 is a potent proteasome inhibitor from the syrbactin natural product family. It was discovered by the company’s founders, Profs. Pirrung and Bachmann of the University of California, Riverside (UCR), and Michigan State University (MSU), respectively. UCR holds multiple patents related to the production of TIR-199 and its use in treating cancers and immune disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: M&A
- Last round: Pre-Seed (Feb 2018)
- Website: hibiskusbio.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/hibiskus-biopharma-1734270 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.